Biotechnology US biotech Mural Oncology has halted all development of its lead candidate, nemvaleukin alfa, after the engineered cytokine failed to meet the primary endpoint in a Phase II melanoma trial — just weeks after a similar failure in ovarian cancer. The company now plans to explore strategic alternatives, including a potential sale. 16 April 2025